Drugmaker MannKind is looking to possibly take its device into the epinephrine market in the wake of the price controversy swirling around Mylan’s EpiPen.

The company’s strategy is focused on bringing more competition to the  emergency epinephrine market that has been dominated by Mylan’s increasingly expensive EpiPen. MannKind is proposing to offer allergy sufferers a needle-free option.